论文部分内容阅读
曾有人提出对淋巴网细胞瘤患者早期作牌切除以确定有无脾脏的侵犯,作为疾病分期和指导治疗的依据。脾切除能增强患者对放射治疗及(或)全身化疗的耐受性。既然脾切除对患者有近期疗效,就需要进一步确定牌切除是否具有这种远期疗效。因此,作者鉴定两组淋巴网细胞瘤(每组20例)患者的长期随访结果。第一组为切脾组,于化疗前作脾切除;第二组为对照组,不作脾切除。两组患者的病情及化疗情况均相类似。使用的诱导化疗均为MOPP方案(氮芥,长春新碱,甲基苄肼,强的松)。将治疗后生存期超过3(1/2)年患者的资料进行
It has been proposed in early lymphatic cytoma patients with card resection to determine the presence or absence of spleen violations, as the basis for disease staging and guiding treatment. Splenectomy can enhance patient tolerance to radiotherapy and / or systemic chemotherapy. Since splenectomy has a short-term effect on patients, it is necessary to further determine whether the brand resection has such long-term efficacy. Therefore, the authors identified long-term follow-up of patients in both groups with lymphoblastoma (20 in each group). The first group was splenectomy group, which was treated by splenectomy before chemotherapy. The second group was control group, not splenectomy. Two groups of patients with similar conditions and chemotherapy. Induction chemotherapy used were MOPP regimens (mechlorethamine, vincristine, procarbazine, prednisone). The survival of patients after treatment more than 3 (1/2) years of patient data